Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pepsi fulfills Rockstar dream

This article was originally published in The Tan Sheet

Executive Summary

The Purchase, N.Y.-based beverage giant enters a multiyear agreement to distribute Rockstar energy drink, the No. 3 brand in the category, according to Information Resources Inc. sales data for the 52 weeks ending Jan. 25 from supermarkets, drugstores and mass merchandise outlets, excluding Wal-Mart. Rockstar, made by Rockstar International, sold $99.1 million during that period and captured 11 percent market share. A number of Pepsi energy drinks in the Amp line are in the top 20, but none claim more than 4 percent of the segment. The distribution deal, the terms of which were not disclosed, "is a major milestone" in Pepsi's bid to become the energy drink category leader, Hugh Johnston, president of Pepsi-Cola North America Beverages, says Feb. 19. Industry experts say to move up in the energy drink market, large firms must pursue deals like Pepsi's with Rockstar, given the "first mover advantage" of Red Bull and Hansen Natural's Monster (1"The Tan Sheet" Sept. 8, 2008, p. 11)

You may also be interested in...

Market Experts See Energy Drink Growth Flagging, Dominant Players Reigning

Beverage industry experts foresee the explosive growth rate of the energy drink market falling to earth during the next five years, as products have virtually saturated the market and new customer segments have failed to materialize

Long Hot Summer For Novel Drug Reviews Forecast At US FDA

Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.

Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza

The latest drug development news and highlights from our US FDA Performance Tracker.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts